Is bevacizumab an immunotherapy? Drug Classification

Bevacizumab is a recombinant humanized monoclonal antibody that is widely used in the treatment of a variety of malignant tumors, such as metastatic colorectal cancer, non-small cell lung cancer, renal cancer, and cervical cancer. However, from the perspective of drug classification, bevacizumab does not belong to immunotherapy, but is classified as an anti-angiogenic targeted therapy drug. Its main mechanism of action is not to kill tumors by activating the patient's immune system, but by targeting and inhibiting vascular endothelial growth factorA (VEGF-A), thereby blocking the formation of new blood vessels in the tumor, inhibiting the tumor's nutrient supply and slowing down its spread.

Immunotherapy drugs, such asPD-1 inhibitors (nivolumab), PD-L1 inhibitors (ateezolizumab) or CTLA-4 inhibitors, mainly enhance the body's immune response by activating T cells or releasing immune suppression mechanisms, thereby eliminating tumor cells. As an inhibitor of the VEGF pathway, bevacizumab's intervention point is more focused on the vasculature in the tumor microenvironment, and its direct regulatory effect on immune cells is limited. Therefore, although it is a biological agent and is often used in combination with immunotherapy, it cannot be classified as an immunotherapy based on its pharmacological mechanism.

In actual treatment, bevacizumab is often used in combination with other chemotherapy drugs or immune checkpoint inhibitors to achieve a more comprehensive anti-tumor effect. For example, in some treatment plans for advanced non-small cell lung cancer, bevacizumab is combined with atezolizumab to simultaneously block tumor angiogenesis and activate the immune system, thereby improving the efficacy. However, this "combination treatment" does not change the drug properties of bevacizumab. It is still one of the targeted anti-angiogenesis treatments.

In summary, bevacizumab is an anti-angiogenic monoclonal antibody among targeted therapies and does not fall into the narrow category of immunotherapy. Understanding its mechanism of action and drug classification will help patients correctly understand the treatment plan, avoid confusing it with immune drugs, and provide scientific basis for formulating personalized anti-cancer strategies.

Reference materials:https://www.drugs.com/bevacizumab.html